- Conditions
- Infection, Human Immunodeficiency Virus
- Interventions
- GSK1265744 Oral, GSK1265744 LAP 800mg intramuscular injection, GSK1265744 LAP 200mg subcutaneous injection, GSK1265744 LAP 200mg intramuscular injection, GSK1265744 LAP 400mg intramuscular injection, TMC278 LA 1200mg intramuscular injection, TMC278 LA 600mg intramuscular injection
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1-infection, Pregnancy, Postpartum
- Interventions
- CAB LA 600mg, RPV LA 900mg, CAB LA 400mg, RPV LA 600mg
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- La Jolla, California • Los Angeles, California • Baltimore, Maryland + 1 more
- Conditions
- HIV Infections
- Interventions
- CAB LA+RPV LA
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Sacramento, California • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
- Interventions
- Cabotegravir Injectable Suspension, Rilpivirine Injectable Suspension
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Bakersfield, California • Fort Lauderdale, Florida • Ft. Pierce, Florida + 7 more